STARPHARMA REPORTS POSITIVE RESULTS WITH VIVAGEL.Starpharma Holdings Limited, Melbourne, Australia, has presented results of a clinical trial indicating that 3% SPL (1) (Systems Programming Language) The assembly language for the HP 3000 series. See assembly language for an SPL program example. (2) (Structured Programming Language) See structured programming. 1. 7013 Gel (VivaGel(TM)) was well-tolerated in men, and suitable for further development as a topical microbicide for the prevention of HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and genital herpes. The results were presented by Starpharma in Sydney at the 4th International AIDS Society The International AIDS Society (IAS) is an international society for scientists, health care and public health workers, and others engaged in HIV/AIDS prevention, control and care. (IAS See iPlanet Application Server. 1. (computer) IAS - The first modern computer. It had main registers, processing circuits, information paths within the central processing unit, and used Von Neumann's fetch-execute cycle. ) Conference on HIV Pathogenesis, Treatment and Prevention, at which the research and development of microbicides was a key focus. The study compared 36 circumcised and uncircumcised uncircumcised Urology Referring to a ♂ or penis which has not been circumcised. See Circumcision. men who applied VivaGel(TM) (24 men) or a placebo gel (12 men) topically to their penis once daily for seven days. The trial was double blinded so that the participants, principal investigator and study staff did not know who was receiving placebo or VivaGel(TM). Overall, this study demonstrated that VivaGel(TM) was safe and well tolerated, and comparable with placebo when applied to the penis of both circumcised and uncircumcised healthy male volunteers once daily for seven days, and left in place for approximately 9 hours. As seen in a previous completed clinical trial in women, there was no evidence of absorption of the active ingredient of VivaGel(TM), SPL7013, into the blood after topical application. The most commonly reported genital adverse events in both treatment groups were considered to be mild and to be consistent with application to the surface of the penis of a substance which dries and is not washed off for a number of hours. Acceptability was a secondary endpoint in this study and interviews indicated that VivaGel(TM) would be acceptable to participants if shown to be protective against sexually transmitted infections, and there were few concerns around the potential impact on sexual pleasure. The clinical study was conducted at the Melbourne Sexual Health Centre, in collaboration with the Burnet Institute and the National Centre in HIV Epidemiology and Clinical Research, and was funded with U.S. Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. ), Department of Health and Human Services Noun 1. Department of Health and Human Services - the United States federal department that administers all federal programs dealing with health and welfare; created in 1979 Health and Human Services, HHS (Contract No. HHSN HHSN Harper Hospital School of Nursing 266200500042C). VivaGel(TM) is being developed as a topical vaginal microbicide for the prevention of HIV and genital herpes, and is currently under investigation in healthy female volunteers in two separate expanded safety clinical trials at four sites in the U.S. and Kenya. VivaGel(TM) also shows promise as a contraceptive agent. Potential as a condom coating VivaGel(TM) is also being explored as a condom coating following the recent signing of an agreement with a leading international condom company. The agreement includes a program of evaluation and development and also commercialization rights covering condoms with VivaGel(TM) coatings within a specified geographical region. The condom company, whose name may not be disclosed for reasons of confidentiality, holds the leading market position within that region. The market in question is in the developed world, and ranks within the top five globally, measured by GDP GDP (guanosine diphosphate): see guanine. . The terms of the agreement were not disclosed. About Starpharma: Starpharma Holdings Limited is a world leader in the development of dendrimer den·dri·mer n. A polymer in which the atoms are arranged in many branches and subbranches along a central backbone of carbon atoms. Also called cascade molecule. nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic dendritic /den·drit·ic/ (den-drit´ik) 1. branched like a tree. 2. pertaining to or possessing dendrites. den·drit·ic adj. Relating to the dendrites of nerve cells. Nanotechnologies, Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents. The company's lead pharmaceutical development product is VivaGel(TM) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes. For more information, visit http://www.starpharma.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion